Department of Medicine, University of Cambridge, Cambridge, UK.
Refractory Respiratory Inflammation DPU, Respiratory TAU, GlaxoSmithKline, Stevenage, UK.
Thorax. 2019 Jul;74(7):659-666. doi: 10.1136/thoraxjnl-2018-212509. Epub 2019 Jan 23.
There is a need to develop imaging protocols which assess neutrophilic inflammation in the lung.
To quantify whole lung neutrophil accumulation in (1) healthy volunteers (HV) following inhaled lipopolysaccharide (LPS) or saline and (2) patients with COPD using radiolabelled autologous neutrophils and single-photon emission computed tomography/CT (SPECT/CT).
20 patients with COPD (Global initiative for chronic obstructive lung disease (GOLD) stages 2-3) and 18 HVs were studied. HVs received inhaled saline (n=6) or LPS (50 µg, n=12) prior to the injection of radiolabelled cells. Neutrophils were isolated using dextran sedimentation and Percoll plasma gradients and labelled with Technetium (Tc)-hexamethylpropyleneamine oxime. SPECT was performed over the thorax/upper abdomen at 45 min, 2 hours, 4 hours and 6 hours. Circulating biomarkers were measured prechallenge and post challenge. Blood neutrophil clearance in the lung was determined using Patlak-Rutland graphical analysis.
There was increased accumulation of Tc-neutrophils in the lungs of patients with COPD and LPS-challenged subjects compared with saline-challenged subjects (saline: 0.0006±0.0003 mL/min/mL lung blood distribution volume [mean ±1 SD]; COPD: 0.0022±0.0010 mL/min/mL [p<0.001]; LPS: 0.0025±0.0008 mL/min/mL [p<0.001]). The accumulation of labelled neutrophils in 10 patients with COPD who underwent repeat radiolabelling/imaging 7-10 days later was highly reproducible (0.0022±0.0010 mL/min/mL vs 0.0023±0.0009 mL/min/mL). Baseline interleukin (IL)-6 levels in patients with COPD were elevated compared with HVs (1.5±1.06 pg/mL [mean ±1 SD] vs 0.4±0.24 pg/mL). LPS challenge increased the circulating IL-6 levels (7.5±2.72 pg/mL) 9 hours post challenge.
This study shows the ability to quantify 'whole lung' neutrophil accumulation in HVs following LPS inhalation and in subjects with COPD using autologous radiolabelled neutrophils and SPECT/CT imaging. Moreover, the reproducibility observed supports the feasibility of using this approach to determine the efficacy of therapeutic agents aimed at altering neutrophil migration to the lungs.
需要开发评估肺部中性粒细胞炎症的成像方案。
使用放射性标记的自体中性粒细胞和单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)来量化(1)健康志愿者(HV)吸入脂多糖(LPS)或生理盐水后和(2)COPD 患者的全肺中性粒细胞积聚。
研究了 20 名 COPD 患者(慢性阻塞性肺疾病全球倡议(GOLD)阶段 2-3)和 18 名 HV。HV 在注射放射性标记细胞之前接受吸入生理盐水(n=6)或 LPS(50μg,n=12)。使用葡聚糖沉淀和聚蔗糖血浆梯度分离中性粒细胞,并使用锝-六甲基丙烯胺肟标记。在 45 分钟、2 小时、4 小时和 6 小时时对胸部/上腹部进行 SPECT。在挑战前和挑战后测量循环生物标志物。使用 Patlak-Rutland 图形分析确定肺中血液中性粒细胞的清除率。
与生理盐水组相比,LPS 组和 COPD 组的肺中 Tc-中性粒细胞的积聚增加(生理盐水:0.0006±0.0003mL/min/mL 肺血分布容积[均值±1SD];COPD:0.0022±0.0010mL/min/mL[P<0.001];LPS:0.0025±0.0008mL/min/mL[P<0.001])。10 名 COPD 患者在 7-10 天后重复放射性标记/成像,其标记中性粒细胞的积聚高度可重复(0.0022±0.0010mL/min/mL 与 0.0023±0.0009mL/min/mL)。与 HV 相比,COPD 患者的白细胞介素(IL)-6 水平基线升高(1.5±1.06pg/mL[均值±1SD]与 0.4±0.24pg/mL)。LPS 挑战后 9 小时,循环 IL-6 水平升高(7.5±2.72pg/mL)。
这项研究表明,使用自体放射性标记的中性粒细胞和 SPECT/CT 成像,可以量化 HV 吸入 LPS 后和 COPD 患者的“全肺”中性粒细胞积聚。此外,观察到的可重复性支持使用这种方法来确定旨在改变中性粒细胞向肺部迁移的治疗剂的疗效的可行性。